Nephroblastoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Nephroblastoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of CEB-01 for Children with Resectable Tumors https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ceb-01-for-children-with-resectable-tumors/ Wed, 29 Apr 2026 15:04:35 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ceb-01-for-children-with-resectable-tumors/ This clinical trial is focused on studying certain types of childhood cancers, specifically those that can be surgically removed from the abdomen. The cancers being studied include extracranial malignant rhabdoid tumor, desmoplastic small round cell tumor, germ cell tumor, Wilms tumor, synovial sarcoma, high-risk neuroblastoma, soft-tissue sarcoma, and fibrolamellar hepatocellular carcinoma. The treatment being tested is a new formulation called CEB-01, which contains the active substance 7-ethyl-10-hydroxycamptothecin. This substance is delivered through a special material that can be implanted in the body.

The purpose of the study is to evaluate the safety and tolerability of CEB-01 when used alongside standard cancer treatments. The study will involve children from birth to under 18 years of age who have these specific types of tumors. Participants will receive the new treatment in addition to their usual care, and the effects will be compared to those who receive only the standard treatment. The study will monitor for any side effects and how well the treatment works in preventing the cancer from coming back or spreading.

Throughout the study, researchers will collect information on the participants’ health and how their bodies process the treatment. This includes measuring the levels of the drug in the blood and observing any changes in the tumors. The study aims to provide valuable information on the potential benefits and risks of using CEB-01 in treating these childhood cancers.

]]> Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients https://clinicaltrials.eu/trial/study-comparing-vincristine-actinomycin-d-and-doxorubicin-with-vincristine-carboplatin-and-etoposide-for-stage-iv-childhood-kidney-cancer-patients/ Wed, 29 Apr 2026 14:29:07 +0000 https://clinicaltrials.eu/trial/study-comparing-vincristine-actinomycin-d-and-doxorubicin-with-vincristine-carboplatin-and-etoposide-for-stage-iv-childhood-kidney-cancer-patients/ This clinical trial is focused on studying a type of cancer known as Stage IV childhood renal tumor, which is a kidney cancer in children that has spread to other parts of the body, such as the lungs. The study is comparing two different treatment combinations to see which is more effective. The first treatment combination, known as the standard arm, includes the drugs Vincristine, Actinomycin-D, and Doxorubicin (VAD). The second treatment combination, called the experimental arm, includes Vincristine, Carboplatin, and Etoposide (VCE).

The purpose of the study is to determine if the experimental treatment (VCE) is not worse than the standard treatment (VAD) in terms of how well it works in shrinking the cancer before surgery. The study will involve giving the treatments to patients for a period of six weeks before surgery. During this time, doctors will monitor how the cancer responds to the treatments, particularly looking at how the cancer in the lungs and other areas responds.

Participants in the study will receive one of the two treatment combinations through an intravenous method, which means the medication is given directly into a vein. The study will help doctors understand which treatment is more effective in treating this type of cancer in children. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study aims to improve the treatment options available for children with this serious condition.

]]> Study on Metronomic Chemotherapy for Children and Teenagers with Relapsed or Refractory Wilms Tumor Using Vincristine, Irinotecan, Etoposide, Temozolomide, and Isotretinoin https://clinicaltrials.eu/trial/study-on-metronomic-chemotherapy-for-children-and-teenagers-with-relapsed-or-refractory-wilms-tumor-using-vincristine-irinotecan-etoposide-temozolomide-and-isotretinoin/ Wed, 29 Apr 2026 14:29:01 +0000 https://clinicaltrials.eu/trial/study-on-metronomic-chemotherapy-for-children-and-teenagers-with-relapsed-or-refractory-wilms-tumor-using-vincristine-irinotecan-etoposide-temozolomide-and-isotretinoin/ This clinical trial is focused on studying a type of kidney cancer known as Wilms tumor, which primarily affects children. The trial is investigating a treatment approach called metronomic chemotherapy, which involves using lower doses of chemotherapy drugs given more frequently. The medications being tested in this study include Vincristine, Irinotecan, Etoposide, Temozolomide, and Cis-Retinoic acid. These drugs are used to see if they can help control the disease in patients whose cancer has returned or has not responded to previous treatments.

The purpose of the study is to evaluate the safety and effectiveness of this treatment approach. Participants will receive the chemotherapy drugs over a period of approximately six months. The study will monitor how well the treatment controls the cancer and any side effects that may occur. The trial is divided into two stages: the first stage focuses on assessing the safety and feasibility of the treatment, while the second stage evaluates its effectiveness in controlling the disease.

Throughout the study, participants will undergo regular assessments, including imaging tests like MRI or CT-scan, to track the progress of the treatment. The study aims to determine if this combination of drugs can help manage the cancer more effectively and improve the quality of life for patients with relapsed or refractory Wilms tumor. The trial will also collect information on any adverse events or side effects experienced by participants during the treatment period.

]]>